

Responsible use of cephalosporins experience and observations

Valérie Thomas
IFAH-Europe



Statement

- IFAH Europe fully supports the global frame of responsible use notably for modern antibiotics
- Overall industry made very positive experience with the implementation of responsible use for modern antibiotics e.g. cephalosporins



Experience / value of responsible use measures

– Prescription only	++
– Parenteral & individual treatm.	+++
– SmPC recommendations	+++
– Susceptibility testing	+++
– Surveillance	+++
– Reserve antibiotics	-
– Restricted indications	(+)




Volumes used of modern cephalosporins



Modern cephalosporins account for less than 1% of the total use of antibiotics in (kg) in pets and food producing animals (*Maran, Danmap, Afssa*)

The very low extent of use is a result of responsible use guidelines and the SmPC recommendations




Susceptibility Surveillance

- High quality surveillance data are a prerequisite to control and manage antimicrobial resistance
- The quality of surveillance data has been increased over the years. All license holders must participate in a pan-European program.
- The low rate of resistance to modern cephalosporins is a direct result of the responsible use measures




Ineffective responsible use measures

- Reserve antibiotics
 - Older compounds to select for resistance
 - Emergence of population with pre-selected antibiotic co- and cross-resistance
- Limitations of indications
 - Has no measurable effect when volumes of use are already very low
 - Therapeutic range of available medicines should not be excessively limited



Conclusions

- Responsible use of modern antibiotics is necessary and there are very effective measures in place to contain antimicrobial resistance
- Susceptibility surveillance programs must be further developed
- Research is required to better understand resistance before putting new measures into place



Thank you for your attention

